Loading...

Ocean Biomedical, Inc.

OCEA•NASDAQ
Healthcare
Biotechnology
$0.007
$0.00(4.76%)

Ocean Biomedical, Inc. (OCEA) Stock Overview

Explore Ocean Biomedical, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 63.0/100

Key Financials

Market Cap4.4M
P/E Ratio-0.12
EPS (TTM)$-0.91
ROE0.26%

AI Price Forecasts

1 Week$0.00
1 Month$-0.33
3 Months$0.61
1 Year Target$0.09

OCEA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Ocean Biomedical, Inc. (OCEA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.09.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.12 and a market capitalization of 4.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for OCEAStats details for OCEA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for OCEAAnalyst Recommendations details for OCEA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.

CEO

Inderjote Kathuria

Employees

7

Headquarters

Room 325, 55 Claverick Street, Providence, RI

Founded

2021

Frequently Asked Questions

;